Magnetar Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

Magnetar Financial’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-37,385	Closed	-$370K	–	1458
2021 Q4	$370K	Sell	37,385 -24,172	-39%	-$240K	﹤0.01%	1028
2021 Q3	$608K	Buy	61,557 +353	+0.6%	+$3.52K	0.01%	843
2021 Q2	$632	Sell	61,204 -2,747	-4%	-$27.9K	0.01%	830
2021 Q1	$655K	Hold	63,951	–	–	0.01%	770
2020 Q4	$693K	Buy	+63,951	New	+$679K	0.01%	527

Other funds holding MLTX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Magnetar Financial's MLTX Position: Q1 2022 in Review

Magnetar Financial sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2022, closing a stake of 37,385 shares — an estimated $370K sold.

Magnetar Financial first reported a position in MLTX in Q4 2020 and held it in 5 quarters. The position peaked at $693K in Q4 2020. 27 funds tracked by Wall St. Rank hold MLTX as of Q1 2022.

Magnetar Financial reported no remaining MoonLake Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
Magnetar Financial sold 37,385 MoonLake Immunotherapeutics shares in Q1 2022, an estimated $370K.
Magnetar Financial first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 5 quarters.
Magnetar Financial's MoonLake Immunotherapeutics position peaked at $693K in Q4 2020.
27 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2022.

Based on Magnetar Financial's 13F filing for Q1 2022, filed 16 May 2022.